Data from the pivotal GEOMETRY mono-1 phase II study show treatment with Tabrecta (capmatinib, formerly INC280) resulted in positive overall response rates among adult patients with metastatic non-small cell lung cancer whose tumors have a mutation that leads to skipping of MET exon 14. Positive duration of response was also observed.
The Biden administration has left NIH in a weakened state, intensifying politicization of science on Capitol Hill and eroding the bipartisan support the government’s premier biomedical research agency has traditionally enjoyed.
